Prognostication model for KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL). CIR, cumulative incidence of relapse; DFS, disease-free survival; gKMT2A, genomic fusion assay for KMT2A; MRD, measurable residual disease; OS, overall survival. Professional illustration by Patrick Lane, ScEYEnce Studios.